A real world study assessing the effectiveness of Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks in patients with Hepatitis-C genotype 1-4 who are DAA-experienced
Latest Information Update: 29 Jul 2020
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 29 Jul 2020 New trial record